Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. Bellmunt J, Lalani AKA, Jacobus S, et al. Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. Br J Cancer. 2018;119(6):707-712. doi:10.1038/s41416-018-0261-0 Read more